Peptides for women over 50: bone, muscle and healthy ageing

Are there peptides for osteoporosis or bone density after menopause?

Yes, but only prescription peptides have fracture data. Teriparatide and abaloparatide cut new spine fractures by roughly two-thirds or more in large trials. MOTS-c and BPC-157 have animal data only, despite a July 2026 FDA advisory vote on MOTS-c. Oral collagen showed small gains in one trial.

Medically reviewedRead →

Am I losing muscle on a GLP-1, and how do I prevent it?

Losing some muscle on a GLP-1 is real — a meaningful share of any large weight loss is lean mass. But it's largely preventable: keep protein high (around 1.6 g/kg/day, eaten first when appetite is low), do resistance training two to four times a week, and don't crash the pace. Peptides are minor next to those levers.

Medically reviewedRead →

Are peptides safe after breast cancer or with a hormone-sensitive cancer history?

No peptide has been tested for safety in breast cancer survivors, so caution follows mechanism. GH-releasing peptides raise IGF-1, which large studies link to ER-positive breast cancer, and kisspeptin activates the reproductive hormone axis, making both oncologist decisions. BPC-157 and TB-500 raise an unproven blood-vessel concern, while GLP-1 drugs have the most reassuring data so far.

Medically reviewedRead →

Are peptides safe and worth it for older adults and seniors?

Older adults are drawn to peptides for muscle and frailty, recovery, skin, and metabolic health — but age changes the risk calculus. More medications mean more interaction risk, kidney and liver function decline, and higher baseline cancer risk matters for anything raising IGF-1. Most peptides are unstudied in seniors, and the proven healthy-aging levers remain exercise, protein, and sleep.

Medically reviewedRead →

Are peptides safe for someone in their 70s, 80s or 90s?

For most compounds people ask about, nobody knows — the trials were never run, or were run in people decades younger. The approved GLP-1 drugs are the partial exception, and their evidence in older adults carries a real warning: muscle mass, grip strength and gait speed decline, and fragility fracture risk is modestly elevated (HR 1.11 in a cohort of over 46,000 adults aged 65+). Age changes the consequences of being wrong, not just the dose.

Medically reviewedRead →